Biotech Values

[mcbio]

Re: ARYX

In any case I lightened my holdings by about 50% last week assuming a delay till Q1 of 10.

I assume you got in just after the tecarfarin debacle at a much lower price and are just taking some profits off the table (never any shame in taking some good profits). Otherwise, I wouldn't (and in fact have not) sell shares at this point. If you are reasonably confident a significant deal is going to get done for budiodarone at some point, whether that be in one month or by 1Q10, then why sell now? The stock still looks pretty cheap to me at this point even after the nice rebound after the tecarfarin debacle as it's still at a sub-$100 million market cap.